-
Nature sub-journal: Dual-specific CRISPR/Cas nanosystem controls precise treatment of liver disease
Time of Update: 2022-10-06
1038/s41392-022-01071-2——List of recent popular activities——▼August 25, research on the upstream production process of GMP-grade lentiviral vectors▼August 29, Phase 2: Immunometabolism Analysis, Helping Cellular Immunotherapy▼August 30, technical application and safety quality control of virus clearance researchAugust 24, 2022 / eMedClub News / -- In recent years, the CRISPR-Cas system has shown great application prospects in the treatment of hereditary and non-hereditary liver diseases .
-
Treatment Essentials for Ulcerative Colitis in Adults (Part 2) 2022 PANCO Clinical Practice Guidelines Recommended at a Glance
Time of Update: 2022-10-03
(Recommended level: strong; Quality of the evidence: low) Practice points: In patients with mild to moderate UC, no difference was found in the maintenance of remission with conventional or extended-release oral mesalazine at equivalent doses.
-
Express A New Hope for Hepatitis B? Innovative therapies are expected to stop viral replication, and the results of the experiment are positive
Time of Update: 2022-10-03
▲If you have any business needs, please long press to scan the QR code above, or▎Editor of WuXi AppTec content teamBeam Therapeutics today announced the latest preclinical positive data for its multi-base editing platform.
-
Case study endoscopy found an esophageal mass, resembling a subesophageal mucosal tumor, but in fact ...
Time of Update: 2022-10-03
Figures A to E ask: What is the most likely diagnosis of an esophageal mass?The answer is revealed: hamartoma of the lower pharynxDuring endoscopic resection, the esophageal mass was found to be a long-stemmed polyp-like mass originating from the right epiglottis that protruded into the upper esophageal segment and resembled a submucosal tumor of the esophagus (Figure F).
-
Climbing to the top, T-DXd brings new options for post-line treatment of HER2-positive advanced gastric cancer
Time of Update: 2022-10-03
Patient baseline demographics and clinical features[7] In the main cohort, the clinical efficacy of T-DXd in HER2-positive advanced gastric cancer was significantly better than that of physician-selected chemotherapy, and the results were published simultaneously at the 2020 ASCO Conference and the New England Journal of Medicine (NEJM).
-
The management of acute fatty liver in pregnancy, are you clear about these 9 issues?
Time of Update: 2022-10-03
Q3How to assess the preoperative risk of a pregnant woman with AFLP?Serum TBil, prothrombin activity (PTA), or international normalized ratio (INR), fibrinogen, platelet count, serum lactic acid, serum creatinine level, and duration of the disease are recommended as indicators of preoperative risk assessment (GRADE grade: 2C).
-
Hepatology Xi'an Jiaotong University Li Zongfang/Lv Shemin et al. revealed the mechanism by which the spleen-hepatic axis mediates liver pathogenesis
Time of Update: 2022-10-03
These cells are aggressively recruited to the fibrotic liver and converted to macrophage phenotypes, promoting intrahepatic Ly6Clo MoMFs accumulation and exacerbating liver fibrosis by activating HSCs. This study provides direct evidence to explain the pathogenesis of splenocyte migration to fibrotic liver, showing that the spleen-hepatic axis plays an important regulatory role in participation in liver disease.
-
BMJ: Low molecular weight heparin for thromboprophylaxis does not prolong colorectal cancer survival
Time of Update: 2022-10-03
(If you need the original text of the literature, you can add the small editor WeChat yxj_oncology to get)1BMJ: Prolonged perioperative use of low-molecular-weight heparin for thromboprophylaxis does not improve disease-free or overall survival in patients with colorectal cancer who undergo surgical resection4.
-
Express The First FDA-Approved Therapy! Patients with hepatorenal syndrome are greeted with new treatment options
Time of Update: 2022-10-03
The new drug gives doctors the first FDA-approved option to treat patients with type 1 hepatorenal syndrome, which will have the potential to improve kidney function and reduce the need for renal replacement therapies such as dialysis.
-
List of recommendations for the Guidelines for Screening of Chinese Liver Cancer (2022, Beijing).
Time of Update: 2022-10-03
Question 16: Recommendations for common surveillance programs for liver cancer: Based on the multi-dimensional evidence of the effectiveness, safety, accessibility and economy of monitoring in high-risk populations of liver cancer, it is recommended to use US combined AFP detection as a monitoring technology in the Chinese population, with a monitoring interval of 12 months, of which the recommended monitoring interval for patients with chronic liver disease (including cirrhosis, chronic hepatitis, etc.
-
Diagnosis and treatment of "fecal incontinence", list of recommendations from the latest guidelines
Time of Update: 2022-10-03
(Very low-quality evidence)Second-line treatment: surgery21.
(Very low-quality evidence)Second-line treatment: surgery21.
(Very low-quality evidence)Second-line treatment: surgery21.
PPTNS therapy (Percutaneous retrotibial nerve stimulation) can be used as a second-line treatment for patients with FI.
-
【CELL DISCOV】The team of Tang Fuyi/Fu Wei used single-cell analysis to reveal the molecular basis of malignant phenotype and tumor microenvironment of small bowel adenocarcinoma
Time of Update: 2022-10-03
This article is the original of the translational medicine network, please indicate the source when reprinting Author: MiaSmall bowel adenocarcinoma (SBA) is a rare malignant tumor with high mortality
-
Corning Jerry releases the latest data on KN026 in combination with KN046 for the treatment of first-line HER2-positive gastric/gastroesophageal joint cancer
Time of Update: 2022-10-03
As of January 30, 2022, a total of 31 patients with HER2-positive locally advanced unresectable or metastatic gastric/gastroesophageal junction cancer (GC/GEJ) who had not previously received systematic treatment were enrolled in the group, and 27 patients received at least one tumor evaluation: objective response rate (ORR) was as high as 77.
-
Is first-line alotinib maintenance therapy feasible in patients with ESMO Voice of China mCRC? The results of the ALTER-C001 test update are available
Time of Update: 2022-10-03
Reviewer: TravelerTypesetting: YoushiExecutive: TouristENDThe 2022 European Society for Internal Oncology (ESMO) Annual Meeting was held in Paris from September 9 to 13 local time.
Reviewer: TravelerTypesetting: YoushiExecutive: TouristENDThe 2022 European Society for Internal Oncology (ESMO) Annual Meeting was held in Paris from September 9 to 13 local time.
-
Professor Fu Xiaohui, Professor Tang Zhaohui and Professor Shi Yinghong had a big coffee conversation and talked about the BTC transformation therapy model and the future development of the Sword and Gall Heroes
Time of Update: 2022-10-03
*For medical professionals onlyBig coffee dialogue, pointing out the future development direction of BTC, come and punch in!In 2022, the expert interview of sofantinib "Sword and Bladder Hero Club" wa
-
Why can liver cancer occur without underlying liver disease? Case learning
Time of Update: 2022-10-03
Therefore, HCC may also occur in patients without underlying liver disease, although rare.
Therefore, HCC may also occur in patients without underlying liver disease, although rare.
Therefore, HCC may also occur in patients without underlying liver disease, although rare.
-
Express is expected to be the first HER2-targeted colorectal cancer therapy! HER2 dual inhibition therapy was qualified for priority review
Time of Update: 2022-10-03
S. FDA will expedite the review of Tukysa's application for supplementation (sNDA) in combination with HER2 monoclonal antibody trastuzumab for the treatment of adults with HER2-positive, metastatic, unresectable colorectal cancer (mCRC) who have received at least first-line therapy.
-
Lancet Sub-Journal (IF=45) Xu Jianmin's team at Fudan University conducted a randomized controlled trial in Chinese group and found that robotic surgery has more advantages in treating rectal cancer
Time of Update: 2022-10-03
" Multicentre randomised controlled trial" research paper, which was randomized in China to compare surgical quality and long-term oncology outcomes of robotic and traditional laparoscopic surgery in patients with low- to medium-grade rectal cancer, and the results showed that robotic surgery has better tumor removal quality, less surgical trauma, and better postoperative recovery.
-
Eradication of Helicobacter pylori may reduce the risk of stomach cancer! But these groups of people are not suitable
Time of Update: 2022-10-03
For medical professionals to read and referenceNot all infected people are suitable for eradication!Helicobacter pylori (Hp) is closely related to chronic gastritis and peptic ulcer, and the list of carcinogens published by the World Health Organization's International Agency for Research on Cancer shows that Hp belongs to class I carcinogens and can induce gastric cancer and lymphoproliferative gastric lymphoma.
-
How to supplement iron with digestive diseases complicated by iron deficiency anemia? This article makes it clear
Time of Update: 2022-10-03
For medical professionals onlyFull of dry goods, quickly collect ~ Iron deficiency anemia (IDA) refers to a lack of stored iron in the body for various reasons, affecting hemoglobin synthesis and causing small cell hypochromic anemia.
